chlorpromazine + sulpiride + clozapine + olanzapine + risperidone + quetiapine + aripiprazole

This entry represents a collection of seven distinct antipsychotic medications—chlorpromazine, sulpiride, clozapine, olanzapine, risperidone, quetiapine, and aripiprazole—utilized as the pharmacological arm in the ACPIOS (Antipsychotic Combination with Psychosocial Intervention on Outcome of Schizophrenia) clinical trial. Sponsored by Central South University in China, the trial (NCT00654576) evaluated the effectiveness of these individual maintenance treatments when combined with psychosocial interventions versus medication alone in patients with schizophrenia. The group includes both first-generation (typical) antipsychotics, which primarily act as dopamine D2 receptor antagonists, and second-generation (atypical) antipsychotics, which typically target both D2 and serotonin 5-HT2A receptors. Aripiprazole, a key atypical agent in the group, is unique for its partial agonism at D2 and 5-HT1A receptors.

Other names

chlorpromazine + sulpiride + clozapine + olanzapine + risperidone + quetiapine + aripitrazoleACPIOS study drugs